Dataset Information


Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype.

ABSTRACT: Salivary duct carcinoma (SDC) is an uncommon, but aggressive malignant tumor with a high mortality rate. Herein, we reported the detection of somatic KRAS A146T and Q61H mutations in 2 out of 4 (50%) sarcomatoid SDC variants. Transgenic mice carrying the human oncogenic KRAS(G12V), which spatiotemporal activation by tamoxifen (TAM)-inducible Cre recombinase Ela-CreERT in the submandibular gland (SMG) ductal cells, was established and characterized. Visible carcinoma was detected as early as day-15 following oncogenic KRAS(G12V) induction alone, and these tumors proliferate rapidly with a median survival of 28-days accompanied with histological reminiscences to human sarcomatoid SDC variants. Moreover, these tumors were resistant to cetuximab treatment despite augmented EGFR signaling, attesting its malignancy. Our findings suggest that LGL-KRas(G12V);Ela-CreERT transgenic mice could serve as a useful preclinical model for investigating underlying mechanisms and developing potential therapies.


PROVIDER: S-EPMC4642517 | BioStudies | 2015-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC3873752 | BioStudies
2020-01-01 | S-EPMC7162829 | BioStudies
2015-01-01 | S-EPMC4747370 | BioStudies
1000-01-01 | S-EPMC4836617 | BioStudies
2015-01-01 | S-EPMC4336936 | BioStudies
2018-01-01 | S-EPMC6199242 | BioStudies
2020-03-06 | GSE146479 | GEO
1000-01-01 | S-EPMC3057777 | BioStudies
2010-01-01 | S-EPMC3141286 | BioStudies
2020-01-01 | S-EPMC7191603 | BioStudies